| Cat. No. |
Product Name |
Information |
| PC-70022 |
Laniquidar
|
An orally active, third-generation P-glycoprotein inhibitor that inhibits the drug efflux pump P-glycoprotein, resulting in higher concentrations of antineoplastic agents in tumor cells that are multi-drug resistant due to the overexpression of P-glycoprotein.. |
| PC-42649 |
Tariquidar methanesulfonate hydrate
|
A potent, specific P-gp inhibitor with Kd of 5.1 nM. |
| PC-45888 |
Elacridar hydrochloride
|
A potent inhibitor of multidrug resistance (MDR) that fully reverses multidrug resistance CHRC5, OV1/DXR and MCF7/ADR cells to the cytotoxicity of doxorubicin and vincristine with IC50 of 0.02 uM. |
| PC-45137 |
Dofequidar fumarate
|
A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR. |
| PC-45136 |
Dofequidar
|
A novel, orally active quinoline compound that can reverse P-glycoprotein (P-gp)-mediated MDR. |
| PC-42403 |
Polyoxyethylene 40 stearate
|
A non-ionic emulsifying agent that can modulate multidrug resistance and enhances antitumor activity of vinblastine sulfate by modulating substrate-stimulated P-gp ATPase activity. |
